Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for systemic juvenile idiopathic arthritis with active systemic features in children and adolescents
2017-002018-29Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tofacitinib in systemic juvenile idiopathic arthritis (SJIA), sponsored by Pfizer. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on 2017-002018-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002018-29.